4-Amino-5-cyano-7-(D-ribofuranosyl)-7H- pyrrolo(2,3-d)pyrimidine. Antibiotic antimetabolite isolated from Streptomyces toyocaensis cultures. It is an analog of adenosine, blocks RNA synthesis and ribosome function, and is used mainly as a tool in biochemistry.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Toyocamycin. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Toyocamycin. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Toyocamycin. |
| Methoxy polyethylene glycol-epoetin beta | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Toyocamycin. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Quinisocaine. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Toyocamycin. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Ambroxol. |
| Etrasimod | The risk or severity of immunosuppression can be increased when Toyocamycin is combined with Etrasimod. |